CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Canton Strategic Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Canton Strategic Holdings Inc
1200 Route 22 East
Phone: (302) 645-7400p:302 645-7400 BRIDGEWATER, NJ  08807  United States Ticker: CNTNCNTN
Business Summary
Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., is advancing institutional blockchain adoption to drive the digitization of financial markets. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The Company also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer MarkWendland 2/5/2026 11/6/2025
President MarkToomey 11/6/2025 11/6/2025
Chief Financial Officer JacobAsbury 52 12/10/2025 12/10/2025
8 additional Officers and Directors records available in full report.

Business Names
Business Name
CNTN
Farrington Therapeutics LLC
HB Pharma Corp.
HILS
THAR

General Information
Number of Employees: 2 (As of 3/1/2025)
Outstanding Shares: 37,729,847 (As of 1/17/2026)
Shareholders: 39
Stock Exchange: NASD
Federal Tax Id: 842642541
Fax Number: (302) 645-1280


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, February 25, 2026